Antibody Targeting Tumor-Derived Soluble NKG2D ligand sMIC Reprograms NK Cell Homeostatic Survival and Function and Enhances Melanoma Response to PDL1 Blockade Therapy

Journal of Hematology & Oncology
23 Jun, 2020 ,

Fahmin Basher conducted a study to investigate whether co-targeting tumor-released chain-related molecule  enhances the therapeutic outcome of PD1/PDL1 blockade therapy for melanoma. They concluded that a pre-clinical proof-of-concept and a new mechanistic understanding to underscore the significance of antibody targeting chain-related molecule to improve therapeutic efficacy of anti-PD1/PDL1 antibody for MIC/sMIC+ metastatic melanoma patients.